Wysa receives FDA breakthrough device designation for AI led mental health conversational agent

Wysa

12 May 2022 - New peer-reviewed studies demonstrate efficacy in managing chronic pain, depression and anxiety

Wysa has announced that the U.S. FDA has granted breakthrough device designation for its AI-based digital mental health conversational agent for patients 18 years and older with a diagnosis of chronic musculoskeletal pain (defined as pain lasting longer than three months) and depression and anxiety.

Read Wysa press release

Michael Wonder

Posted by:

Michael Wonder